Weiss v. Shree Baidyanath Ayurved Bhawan Pvt. Ltd.

CourtDistrict Court, E.D. New York
DecidedMarch 7, 2025
Docket1:21-cv-00155
StatusUnknown

This text of Weiss v. Shree Baidyanath Ayurved Bhawan Pvt. Ltd. (Weiss v. Shree Baidyanath Ayurved Bhawan Pvt. Ltd.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Weiss v. Shree Baidyanath Ayurved Bhawan Pvt. Ltd., (E.D.N.Y. 2025).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ------------------------------------------------------------- THILO WEISS,

Plaintiff, REPORT & RECOMMENDATION -against- 21-cv-155 (ERK) (JRC) SHREE BAIDYANATH AYURVED BHAWAN PVT. LTD.,

Defendant. ------------------------------------------------------------- JAMES R. CHO, United States Magistrate Judge:

Plaintiff Thilo Weiss (“Weiss” or “plaintiff”) commenced this action against Shree Baidyanath Ayurved Bhawan Pvt. Ltd. (“Baidyanath” or “defendant”) seeking to recover damages on theories of products liability, failure to warn, battery, and intentional infliction of emotional distress for harm plaintiff allegedly suffered after consuming defendant’s “Ayurvedic” supplements.1 See Compl. ¶ 1, ECF No. 1; Am. Compl. ¶ 1.2 Specifically, plaintiff alleges that after ingesting the Ayurvedic supplements he purchased from Baidyanath, he was hospitalized and treated for, among other things, severe lead poisoning. Am. Compl. ¶¶ 1, 4, 45, 48, 49. On April 10, 2024, the Honorable Edward R. Korman granted plaintiff’s motion for default judgment as to Counts I through IV of the Amended Complaint and referred the motion for default judgment (ECF No. 28) to the undersigned for a calculation of damages on Counts I through IV only. See ECF No. 32. For the reasons set for below, this Court recommends

1 The Amended Complaint defines Ayurveda as “a holistic medical approach that originated on the Indian subcontinent.” Am. Compl. ¶ 2, ECF No. 7.

2 Plaintiff initially named ten individual Baidyanath directors and shareholders as defendants (see Compl.), but Weiss later dismissed all claims against the individual defendants. Not. of Voluntary Dismiss., ECF No. 20. awarding plaintiff a total of $2.6 million in damages, consisting of $1.3 million in compensatory damages and $1.3 million in punitive damages. This Court does not recommend awarding damages for future pain and suffering. BACKGROUND3

In January 2019, plaintiff, a resident of New Jersey, traveled to India with his wife to visit his wife’s family. Am. Compl. ¶¶ 19, 37. Plaintiff and his wife “had been trying to start a family for quite some time” and visited an Ayurvedic practitioner for a fertility consultation during their trip. Id. ¶ 37. The Ayurvedic practitioner recommended plaintiff begin taking several Ayurvedic supplements manufactured by defendant: Pushpadhanwa Ras, Shukramatrika Bati and Manmath Ras (the “Supplements”). Id. ¶ 38. Plaintiff purchased the Supplements while in India after having reviewed Baidyanath’s U.S. website, which stated that the Supplements had “no side effects” and offered a “gentle healing touch.” Id. ¶¶ 38–39. Plaintiff returned to the United States on January 20, 2019, and began taking the recommended daily dose of the Supplements (two capsules of each supplement) the following day. Id. ¶ 40. Within a few

weeks, plaintiff “began to notice intermittent tenderness in his abdomen.” Id. ¶ 41. Plaintiff’s symptoms intensified, and he began experiencing abdominal bloating, fatigue, lethargy, and shortness of breath. Id. ¶¶ 42–43. Plaintiff stopped taking the Supplements as a precaution; however, his condition continued to deteriorate. Id. ¶¶ 44–45. After several hospital visits to New York-Presbyterian Weill Cornell Medical Center (“New York-Presbyterian”), plaintiff’s blood tests revealed that he “had been poisoned with a lethal dose of lead.” Id. ¶ 49. At one point, his blood contained lead levels that were eight to ten

3 The following facts taken from the Amended Complaint (ECF No. 7) are assumed to be true for the purpose of this report and recommendation. times greater than the levels considered “high” by the Centers for Disease Control and Prevention (“CDC”). Id. ¶¶ 4, 49, 52. Plaintiff’s “[lead] poisoning was so severe that his doctors had never seen a patient present with [his] symptoms.” Id. ¶ 50. Plaintiff continues to experience symptoms of lead poisoning following treatment in early 2019, including headaches and fatigue, and “doctors are unsure whether [plaintiff’s] body will ever fully purge itself of the

[toxins]” contained in the Supplements. Id. ¶ 58. Staff at New York-Presbyterian provided samples of the Supplements to the New York City Department of Health and Mental Hygiene for testing. Id. ¶ 59; id. Ex. A. The tests revealed that the Supplements contained significantly high and unsafe levels of lead, mercury, and arsenic. Am. Compl. ¶ 59, 60; id. Ex. A; see Mem. and Order dated Apr. 10, 2024, ECF No. 32, at 3. Plaintiff also alleges that prior tests conducted by the U.S. Food and Drug Administration (“FDA”) in 2015 had similarly found that defendant’s Ayurvedic supplements contained “high levels of mercury and lead.” Am. Compl. ¶ 34. In 2016, the Canadian government also issued

an “alert” noting the “high levels of mercury and lead” in defendant’s supplements. Id. On January 12, 2021, plaintiff filed his initial Complaint, see ECF No. 1, and on March 22, 2021, filed his Amended Complaint, see ECF No. 7. In his Amended Complaint, plaintiff alleges claims for strict products liability (Count I), negligent products liability (Count II), strict liability for failure to warn (Count III), negligent failure to warn (Count IV), battery (Count V), and intentional infliction of emotional distress (Count VI). See generally Am. Compl. Upon plaintiff’s application and in light of defendant’s failure to appear or otherwise defend this action, the Clerk of the Court entered default against defendant on September 7, 2022. See Clerk’s Entry of Default, ECF No. 27. On October 7, 2022, plaintiff moved for default judgment against defendant. Mot. for Default J., ECF No. 28. On April 10, 2024, Judge Korman granted in part plaintiff’s motion for default judgment. See ECF No. 32. Judge Korman found that plaintiff had alleged facts sufficient to establish liability on his products liability claims (Counts I through IV), but not as to his intentional tort claims (Counts V and VI), which were barred by the applicable statute of limitations. Id. Judge Korman referred the motion for

default judgment to the undersigned for an assessment of damages on Counts I through IV. Id. DISCUSSION

Although the Court has found that plaintiff’s allegations are sufficient to establish liability on his products liability claims (Counts I through IV), see ECF No. 32, defendant’s default “is not considered an admission of damages.” Greyhound Exhibitgroup, Inc. v. E.L.U.L. Realty Corp., 973 F.2d 155, 158 (2d Cir. 1992) (citing Flaks v. Koegel, 504 F.2d 702, 707 (2d Cir. 1974)). Rather, “the court must conduct an inquiry sufficient to establish damages to a ‘reasonable certainty.’” Gunawan v. Sake Sushi Rest., 897 F. Supp. 2d 76, 83 (E.D.N.Y. 2012) (quoting Credit Lyonnais Sec. (USA), Inc. v. Alcantara, 183 F.3d 151, 155 (2d Cir. 1999)). A court may make this determination based upon evidence presented at a hearing or upon a review of detailed affidavits and documentary evidence. See Fed. R. Civ. P. 55(b)(2); Action S.A. v. Marc Rich & Co., Inc., 951 F.2d 504, 508 (2d Cir. 1991). I. Legal Standards “The assessment of damages following entry of a default judgment in a diversity action is governed by state law standards.” Hinckley v. Westchester Rubbish, Inc., No. 04-CV-189, 2006 WL 2849841, at *4 (S.D.N.Y. Oct. 2, 2006) (citing Consorti v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

House v. Kent Worldwide MacHine Works, Inc.
359 F. App'x 206 (Second Circuit, 2010)
State Farm Mutual Automobile Insurance v. Campbell
538 U.S. 408 (Supreme Court, 2003)
NY Univ. v. CONT'L INS CO
662 N.E.2d 763 (New York Court of Appeals, 1995)
Hill v. Airborne Freight Corp.
212 F. Supp. 2d 59 (E.D. New York, 2002)
Caprara v. Chrysler Corp.
417 N.E.2d 545 (New York Court of Appeals, 1981)
Solomon v. City of New York
512 N.E.2d 546 (New York Court of Appeals, 1987)
Home Insurance v. American Home Products Corp.
550 N.E.2d 930 (New York Court of Appeals, 1990)
Wilson v. City of New York
65 A.D.3d 906 (Appellate Division of the Supreme Court of New York, 2009)
Solis-Vicuna v. Notias
71 A.D.3d 868 (Appellate Division of the Supreme Court of New York, 2010)
Solomon v. City of New York
111 A.D.2d 383 (Appellate Division of the Supreme Court of New York, 1985)
La Fountaine v. Franzese
282 A.D.2d 935 (Appellate Division of the Supreme Court of New York, 2001)
Jackson v. Chetram
300 A.D.2d 446 (Appellate Division of the Supreme Court of New York, 2002)
Guerrero v. Djuko Realty, Inc.
300 A.D.2d 542 (Appellate Division of the Supreme Court of New York, 2002)
Reed v. City of New York
304 A.D.2d 1 (Appellate Division of the Supreme Court of New York, 2003)
Consorti v. Armstrong World Industries, Inc.
103 F.3d 2 (Second Circuit, 1995)
Bouveng v. NYG Capital LLC
175 F. Supp. 3d 280 (S.D. New York, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Weiss v. Shree Baidyanath Ayurved Bhawan Pvt. Ltd., Counsel Stack Legal Research, https://law.counselstack.com/opinion/weiss-v-shree-baidyanath-ayurved-bhawan-pvt-ltd-nyed-2025.